StageBio is excited to introduce you to our new Director of Digital and Quantitative Pathology, our very own Dr. Thomas Lemarchand!
Dr. Lemarchand brings a wealth of experience and passion to this role. As an experienced research and preclinical pathologist, he has broad expertise in molecular and immunopathology, disease models, GLP studies and clinical trials. With years of practice in projects involving in situ hybridization, immunohistochemistry, immunofluorescence and morphometry, he is perfectly positioned to lead this computational pathology program.
Under Dr. Lemarchand’s leadership, StageBio’s digital pathology initiative will be focused on deploying an efficient and user friendly image management and sharing platform for internal users and StageBio clients. Additionally, he’ll accelerate the roll-out of StageBio’s software components and assemble a core imaging team to create a premier pathology bioinformatics service supporting internal and external clients, across divisions and regions.
“We are delighted to have Thomas move to this leadership role with our team,” says Serge Rousselle, Chief Scientific Officer. “Integrating his experience and talent with leading the digital pathology initiative is the natural next step, and it will continue to support our vision of excellence at StageBio.”
Please join the StageBio team in congratulating Dr. Thomas Lemarchand on his new role, Director of Digital and Quantitative Pathology!
About Dr. Thomas Lemarchand
Dr. Thomas Lemarchand performed research in molecular and immunopathology in disease models and worked in pharmaceutical companies, before leveraging this experience in both GLP safety and pharmacology non-GLP studies in CROs. As Director of Digital and Quantitative Pathology at StageBio, Dr. Lemarchand routinely uses in situ hybridization, immunohistochemistry, immunofluorescence and morphometry in studies. He earned his DEDV (DMV) from Nantes University School of Veterinary Medicine in 1992, completed pathology training in 1993 in Montreal and earned his PhD from Louisiana State University in 2000. He became a Diplomate of the European College of Veterinary Medicine in 2015.
StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates six GLP laboratories as well as two GLP specimen archiving facilities in the U.S., with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 25+ board-certified veterinary pathologists and more than 60 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity and client satisfaction.
Learn more at stagebio.com